Sentence examples for mutant cells when from inspiring English sources
As shown in figure 5 the exon 1b (p19ARF) is late replicating in young cells which do not express the Arf or Ink4a genes; whereas this region becomes early replicating in pre-senescent and in M33 mutant cells when the Arf or Ink4a genes are expressed.
Functional studies in fibroblasts supported the potential pathogenicity of coenzyme Q10 deficiency in GLUT1 mutant cells when compared with controls.
There was no significant difference observed in the capsule sizes between wild type and mutant cells when grown on either glucose or inositol medium.
The rik1 gene (a component of Clr4 methyltransferase complex) is similarly silenced in mst2 epe1 mutant cells when clr4 cannot be silenced.
A highly significant reduction of mRNA and sortilin expression levels was observed in mutant cells when compared with their wild-type counterparts and (b)), suggesting that the SORT1 p.G171A mutation identified in our ET patients is implicated in sortilin dysregulation.
For example, it is possible to estimate the total concentration or relative activity of an enzyme in wild-type vs. mutant cells when only one of the kinetic parameters is accurately estimated.
The Tau1 signal was evident in all neurites of double-mutant cells when compared with controls, where the majority of control cells had only one Tau1-positive neurite.
In contrast, GFP-Sufu never accumulates at the tips of cilia in Gli mutant cells, even when it is expressed at a high level as indicated by strong cytoplasmic signals (Fig. 5B and Table 3; n = 0/30 cells).
We observed that the antibody against CCTα did not give any ciliary staining in the mutant cells, even when the body of the cell is clearly labeled (Figure 3 F H compare with E).
Secondly, the spindle was frequently not recognisable in mitotic mutant cells and, when present, it exhibited significant defects in formation, being too short, without poles or bent.
This indeed appears to be the case, with low, sub-lethal doses of each class of drug combining to give selective killing of RAS mutant cells, especially when the proteasome inhibitor treatment is given a day after the DNA damaging agent.
